Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top executives said.

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases

Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as investors gobbled up shares in the company following an announcement that it anticipates the release of a personalized cancer vaccine, which it was developing with Merck Co., by 2027.

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read more here.

A German court ruled that BioNTech (BNTX) and Pfizer (PFE) have to pay Moderna damages because they infringed on Moderna

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with five new international lawsuits. | The companies claim that Moderna stepped on their lipid nanoparticle technology with its COVID vaccine Spikevax and RSV vaccine mRESVIA.

For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of investors to put into their portfolios. Taking a wait-and-see approach may be the safest option today.

Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen. Thank you very much for joining TD Cowen's 45th Annual Healthcare Conference.

The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in the waning days of the Biden administration. “While it is crucial